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Background: Although Mycobacterium fortuitum is not an uncommon organism among the
non-tuberculous mycobacteria isolated from respiratory specimens, its clinical significance
had not been well studied.
Methods: We identified all patients whose respiratory specimens were positive for
M. fortuitum between January 2003 and December 2005. Among 182 patients whose
specimens were positive for M. fortuitum, 26 were positive at least twice. We
retrospectively reviewed their characteristics, and clinical courses.
Results: Of the 26 patients, 15 had two positive culture results for M. fortuitum; the other
11 had three or more. Sixteen patients were male and the median age was 61.5 years.
Major presenting symptoms were cough (65%) and sputum (58%). Most patients had known
underlying lung diseases, including prior tuberculosis (54%), lung cancer (15%), idiopathic
pulmonary fibrosis (15%), and other mycobacterial lung disease (15%). The most common
CT findings were bronchiectasis (80%). Only one patient received specific prolonged
antibiotic therapy against M. fortuitum infection; the other 25 did not. No patients showed
clinical aggravation during the follow-up period, although in five patients their underlying
lung diseases continued to progress. The median follow-up duration was 12.5 months and
none of the patients whose sputum specimens were available had persistent positive
cultures for M. fortuitum.Elsevier Ltd. All rights reserved.
i; ATS, American Thoracic Society; CT, computed tomography; IDSA, Infectious Diseases Society of
complex; NTM, non-tuberculous mycobacteria; RGM, rapidly growing mycobacteria.
4103429; fax: +82 2 34106956.
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S. Park et al.438Conclusion: M. fortuitum usually causes colonization or transient infection in patients
with underlying lung disease, such as prior tuberculosis or bronchiectasis. The majority of
patients may not need to receive prolonged antibiotic therapy for M. fortuitum isolates.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Mycobacteria other than Mycobacterium tuberculosis com-
plex and Mycobacterium leprae are collectively referred to
as non-tuberculous mycobacteria (NTM).1–3 Human disease
resulting from NTM infection is classified into four distinct
clinical syndromes: pulmonary disease, lymphadenitis,
cutaneous disease, and disseminated disease. Among these,
chronic pulmonary disease is the most common localized
clinical condition.1–3 Studies have demonstrated that dis-
ease attributable to NTM is on the rise. NTM are responsible
for an increasing proportion of mycobacterial disease in
many developed and developing countries.4–8
Non-tuberculous mycobacteria are ubiquitous organisms
and are frequently isolated from environmental sources,
including surface water, tap water, and soil.1–3 Accordingly,
the isolation of NTM species from a respiratory sample is
insufficient evidence for the presence of NTM lung disease.
Some patients are infected with NTM without evidence of
pulmonary disease. Such infection may indicate colonization
or transient infection. Thus, the diagnosis of NTM lung disease
must rely on clinical, radiographic, and microbiologic
criteria. The American Thoracic Society (ATS) issued diag-
nostic criteria for NTM lung disease in 1997,1 and the ATS and
the Infectious Diseases Society of America (IDSA) recently
revised the criteria in 2007.2 The guidelines stated that the
recommended diagnostic criteria are more appropriate for
Mycobacterium avium complex (MAC), Mycobacterium kan-
sasii, and Mycobacterium abscessus, and too little was known
about pulmonary disease caused by other NTM to validate the
diagnostic criteria for other organisms.1,2
Mycobacterium fortuitum is one of the rapidly growing
mycobacteria (RGM), which are distinguished from other
NTM by their ability to form colonies in less than 1 week and
their in vitro resistance to antimycobacterials.9 M. for-
tuitum is a commonly isolated organism from respiratory
specimens in clinical laboratories in many countries.4–7 To
date, however, the clinical significance of this organism has
not been well studied. Thus, we sought to investigate the
clinical significance of M. fortuitum recovered from respira-
tory specimens.
Materials and methods
Study subjects
Permission was obtained from the institutional review board
to review and publish information from patients’ records.
Informed consent was waived due to the retrospective
nature of the study.
All patients with positive culture for M. fortuitum from a
mycobacterial laboratory at the Samsung Medical Center (a
1250-bed tertiary referral hospital in Seoul, Korea) during
the 3-year period from January 2003 to December 2005 wereidentified by a computer-assisted search of medical records.
Patients with isolated M. fortuitum recovered from non-
respiratory specimens were excluded.
Smears, cultures, and species identification
Clinical specimens were stained using the Ziehl–Neelsen
method, according to the guidelines of the ATS.10 The
results of smear microscopy were reported semi-quantita-
tively. A positive smear was defined as one with41 acid-fast
bacilli (AFB) per 100 high-power fields.
Sputum or bronchial washing specimens were decontami-
nated using the N-acetyl-L-cysteine/2% NaOH method, and
the processed specimens were plated on Lo¨wenstein–Jensen
media. Inoculated tubes were incubated at 37 1C and then
inspected weekly for 8 weeks. All AFB isolates were assessed
to distinguish between M. tuberculosis and NTM, according
to growth rates, colony morphology, and pigmentation, and
with a commercial DNA probe (Gen-Probe Amplified Myco-
bacterium Tuberculosis Direct Test; Gen-Probe, San Diego,
CA).10 NTM species identification was performed using a
polymerase chain reaction-restriction length polymorphism
method based on the rpoB gene, as previously described.6
Evaluation of clinical and radiographic findings
The medical records of the patients were reviewed,
including their age, gender, respiratory symptoms, smoking
history, body mass index, underlying illness, AFB smear
status, number of positive isolates, and treatment informa-
tion. Chest radiography and available computed tomography
(CT) scan images were reviewed by an experienced chest
radiologist (K.S.L.). Chest radiographic findings were eval-
uated with regard to the presence of reticulonodular
opacities, cavitation, consolidation, and volume loss. The
CT scans were evaluated with regard to the presence or
absence of well-defined nodules, consolidation, cavitation,
and bronchiectasis. Clinical course and outcomes following
positive sputum culture were assessed by chart review.
Clinical improvement was defined as a decrease or
disappearance of the respiratory symptoms (i.e., cough,
sputum, hemoptysis, or fever, etc.) and radiographic
improvement was defined as a decrease or disappearance
of one or more components of the above radiolographic
findings on the follow-up chest radiography or CT scans.
Results
Characteristics of patients with two or more
cultures for M. fortuitum
From January 2003 to December 2005, 182 patients were
identified with positive cultures for M. fortuitum from
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two or more positive culture findings, and 156 patients (86%)
had only one in their two or more sputum specimens for AFB
analysis. We mainly focused on the 26 patients with two or
more positive culture findings in this study, considering
revised diagnostic criteria of NTM lung disease.2
The median age was 61.5 years (range 25–79 years).
Sixteen of the patients were men; 10 were women. Fourteen
patients (54%) had never smoked, six patients (23%) were
ex-smokers, and six (23%) were current smokers. Cough
(n ¼ 17, 65%) and sputum (n ¼ 15, 58%) were the most
common presenting symptoms. Eight patients (31%) exhib-
ited hemoptysis. No patient complained of chronic vomiting
or dysphagia. Seven patients (27%) had underlying non-
pulmonary disease, including diabetes mellitus and chronic
liver disease, such as chronic hepatitis B. No patient was
seropositive for antibodies to human immunodeficiency virus
or was a member of a high-risk group (i.e., homosexuals,
injectable drug users, persons with hemophilia, or coagula-
tion disorder, etc.).
Most patients had known underlying lung diseases. Four-
teen patients (54%) had previous histories of pulmonary
tuberculosis, four patients (15%) had lung cancer, and four
(15%) had idiopathic pulmonary fibrosis. Interestingly, four
patients (15%) had known pulmonary disease due to other
mycobacteria. Three patients were previously diagnosed as
suffering from MAC lung disease and had M. fortuitum
recovered during the course of follow-up without specific
antibiotic therapy for MAC infection. One patient had
positive culture for M. fortuitum during the treatment of
multidrug-resistant tuberculosis after sputum conversion of
M. tuberculosis (Table 1).Table 1 Demographic data of patients (n ¼ 26).
Variable Value
Age (years) 61.5 (25–79)
Male/female 16 (62%)/10 (38%)
Body mass index (kg/m2) 21.2 (16.5–28.4)
Smoking status
Non-smoker 14 (54%)
Ex-smoker 6 (23%)
Current smoker 6 (23%)
Symptoms
Cough 17 (65%)
Sputum 15 (58%)
Dyspnea 10 (38%)
Hemoptysis 8 (31%)
Fever 5 (19%)
Underlying lung disease
Previous pulmonary tuberculosis 14 (54%)
Lung cancer 4 (15%)
Idiopathic pulmonary fibrosis 4 (15%)
Other mycobacterial lung disease 4 (15%)
Data are presented as the median (range) or number (%).
Three patients had Mycobacterium avium complex lung
disease and one patient had multidrug-resistant tuberculosis.Radiographic and CT findings
All 26 patients underwent chest radiography and 25 of them
had available chest CT scan data. The most common
radiographic finding was the presence of reticulonodular
opacities, which were found in 21 (81%) of the 26 patients.
Cavitary lesions and consolidation were observed in five
patients (19%). Lobar volume decrease was seen in four
patients (15%) and was most commonly found in the upper
lung zone (Table 2).
On chest CT, the most common findings were bronchiec-
tasis, which occurred in 20 (80%) of the 25 patients for whom
CT scans were available. Ten of fourteen patients with
previous histories of pulmonary tuberculosis had CTevidence
of sequelae of tuberculosis, such as calcified multiple
parenchymal nodules, atelectasis, and bronchiectasis lo-
cated in the apical and posterior segments of the upper
lobe. Well-defined nodules were identified in 15 patients
(60%). Lobular consolidations were seen in 13 patients (52%).
Cavities were found in five patients (20%); of these, three
had MAC lung disease and one had multidrug-resistant
tuberculosis (Table 2).
Microbiologic findings
Seventy-seven specimens were found to be positive for M.
fortuitum from 26 patients. The isolates were from sputum
specimens (n ¼ 73, 95%) or bronchial washing fluid (n ¼ 4,
5%). The median number of sputum specimens sent for AFB
culture was 9 (range 2–33) and the median number of
positive culture tests was 2 (range 2–7). In the 26 patients,
15 patients (58%) had two positive culture, and 11 (42%) had
three or more positive cultures. AFB smears were positive in
nine patients (35%) and all of these had more than three
positive culture findings.
Antibiotic treatment and follow-up
In the 26 patients with two or more positive culture findings
for M. fortuitum, only one patient received specific
antibiotic therapy for M. fortuitum pulmonary infection.
Specifically, a 53-year-old woman with a history of previous
treatment for pulmonary tuberculosis 30 years earlierTable 2 Radiographic and CT findings.
Variable Value
Radiographic findings
Reticulonodular opacities 21 (81%)
Cavitary lesions 5 (19%)
Consolidation 5 (19%)
Lobar volume decrease 4 (15%)
CT findings
Bronchiectasis 20 (80%)
Nodules 15 (60%)
Consolidation 13 (52%)
Cavitary lesions 5 (20%)
Chest CT scan data were available for 25 patients.
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several years. A chest radiograph and CT revealed multiple
cavitary consolidation in the entire left lung. Numerous
AFB were detected in multiple sputum specimens (4+).
M. fortuitum was consistently isolated, which was suscep-
tible to clarithromycin, ciprofloxacin, doxycycline, and
sulfonamides. The patient was started on a three-drug
regimen of clarithromycin, ciprofloxacin, and sulfamethox-
azole. Her symptoms and radiographic abnormalities im-
proved with continuing antibiotic treatment for 10 months
and negative sputum smear and culture conversion was
achieved and maintained after 1 month of treatment.
The other 25 patients did not receive specific prolonged
antibiotic therapy for M. fortuitum infection. Twelve
patients (46%) received empirical oral antibiotics during an
initial period of aggravation of their symptoms; fluoroqui-
nolones, b-lactam agents, or macrolides were prescribed for
7–14 days in these patients. Three patients (12%) received
anti-tuberculosis drugs, including isoniazid, rifampin,
ethambutol, and pyrazinamide, after the identification of
positive sputum AFB stain results. However, anti-tubercu-
losis therapy was discontinued in these three patients after
the confirmation of M. fortuitum culture findings and they
were then followed without specific antibiotic therapy. Ten
patients (38%) received treatment of their underlying lung
disease or symptomatic treatment, such as mucolytics and
antitussive agents, without antibiotics for M. fortuitum
infection. The clinicians considered the M. fortuitum
isolated from these patients to be organisms of little
significance, which did not necessitate treatment with
specific antibiotic therapy for long periods. Of these
patients, all had alternative explanations for their symp-
toms and abnormal chest radiographs or CT scans, including
community-acquired pneumonia, other mycobacterial in-
fection, and idiopathic pulmonary fibrosis (Table 3).
The median follow-up duration was 12.5 months (range
1–47 months, mean 17 months) in the 25 patients who did
not receive specific antibiotic therapy for M. fortuitum
infection. Patients visited outpatient clinic at 1–3 monthTable 3 Patient management.
Treatment Duration No. of
patients
Empirical antibiotics 12 (46%)
Fluoroquinolones 7–10 days 4
b-Lactam agents plus
macrolides
7–14 days 4
b-Lactam agents 7–14 days 3
Macrolides 7 days 1
Empirical anti-tuberculosis
drugs
3–6
weeks
3 (12%)
Specific antibiotic therapy for
Mycobacterium fortuitum
infection
10
months
1 (4%)
Treatment of underlying
disease or symptomatic
treatment without antibiotics
– 10 (39%)intervals. Among them, nine patients were followed up for
424 months, and four patients were followed up for 436
months. Seven (28%) patients revealed clinical and radio-
graphic improvements during the follow-up period including
four patients with three or more positive cultures. Thirteen
patients (52%) including six patients with three or more
positive cultures showed no change in their symptoms or
chest radiographs. Five patients (20%) with underlying lung
disease, such as lung cancer or idiopathic pulmonary
fibrosis, showed aggravation of symptoms and radiographic
findings due to progression of the underlying lung disease.
Among the 19 patients with available follow-up sputum
results, persistent positive sputum culture findings for M.
fortuitum were not detected.
156 patients with only one positive culture for
M. fortuitum
One hundred and fifty-six patients had only one positive
culture for M. fortuitum in their two or more sputum
specimens for AFB analysis. The median number of sputum
specimens sent for AFB culture was 7 (range 2–46, mean 10).
The median age was 55 years (range 16–91 years). Ninety-
four (60%) patients were men. Forty-eight (31%) patients
had been managed for pulmonary tuberculosis or pulmonary
disease caused by other NTM at the time of positive culture
for M. fortuitum. Thirty-seven (24%) patients had previous
history of pulmonary tuberculosis or other NTM pulmonary
disease. Fifty-seven (37%) patients had other lung diseases
such as bacterial pneumonia, bronchiectasis or chronic
obstructive pulmonary disease. AFB smears were positive
for 11 (7%) patients and all of these had concurrent
pulmonary tuberculosis and other NTM pulmonary disease.
Thirty-two (21%) patients received empirical antibiotics
for 5–14 days for suspicion of bacterial pneumonia or acute
exacerbation of underlying disease such as bronchiectasis or
chronic obstructive pulmonary disease, and 120 patients
received treatment of their underlying lung disease or
symptomatic treatment without antibiotics. During a med-
ian follow-up of 16 months (mean 22 months), continuous
positive sputum culture findings for M. fortuitum were not
discovered in 62 (40%) patients who had available sputum
examinations.
Discussion
To our knowledge, this is the largest case series describing
patients with respiratory specimen cultures positive for M.
fortuitum. We found that M. fortuitum was isolated from
respiratory specimens primarily from patients with under-
lying lung disease, including prior tuberculosis and bronch-
iectasis. M. fortuitum usually caused colonization (i.e.,
recovery of organisms more than once without demonstra-
tion of specific pulmonary disease) or transient infection
(i.e., transient isolation of organisms with subsequent
negative cultures and no evidence of disease progression)
in these patients, rather than progressive pulmonary
disease. In most of the patients with more than two positive
cultures for M. fortuitum, clinical and radiographic findings
were not progressive, even without specific antibiotic
therapy.
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that has been isolated from soil and water.11,12 M. fortuitum
is included in the RGM in which visible colonies can be
produced within 7 days and is one of the pathogenic, non-
pigmented species.13 M. fortuitum can occasionally cause
miscellaneous human infections, including skin and soft
tissue infections, post-surgical wound infections, lymphade-
nitis, and catheter-related infections, but it can also cause
lung disease.14,15
Several reports have described M. fortuitum lung disease,
although most were case studies. M. fortuitum lung disease
usually occurs in patients with pre-disposing factors, such as
malignancy, renal transplantation, chronic reflux disease,
achalasia, bronchiectasis, and cystic fibrosis.16–22 The
presentation of pulmonary disease includes lung ab-
scesses,23–25 pneumonia,26,27 pleural effusions,28 and soli-
tary pulmonary nodules,29 etc. In the current study, most
patients had underlying lung diseases, including prior
pulmonary tuberculosis, bronchiectasis, or other mycobac-
terial lung disease. The most common CT finding in these
patients was bronchiectasis. These findings suggest that
M. fortuitum lung infection occurs commonly in structural
lung disease.
Griffith et al. reported clinical features of pulmonary
disease caused by RGM in 1993.30 In that report,
M. fortuitum was isolated from 15% of patients with
lung disease due to RGM, and was second in prevalence to
M. abscessus. Although Griffith et al. did not describe
detailed clinical characteristics of the patient with
M. fortuitum lung disease, as differentiated from those
with M. abscessus lung disease, they reported that
M. fortuitum occurred as a pathogen only in a subgroup of
patients with gastroesophageal disease, such as achalasia,
chronic vomiting, or exogenous lipoid pneumonia.30 In these
patients, an unusual presentation of widespread alveolar
pulmonary infiltrates, high fever, and leukocytosis was
seen.30 In addition, Hadjiliadis et al. reported 20 patients
with NTM lung disease-associated esophageal disorders.
Most of their patients had achalasia and pulmonary infection
by M. fortuitum.21 In our study, no patient complained of
chronic vomiting or dysphagia, which might suggest a
chronic esophageal disorder. However, specific investigation
for gastroesophageal disease such as esophagogastroscopy
or 24-h esophageal pH monitoring was not performed in this
retrospective study, so we could not definitely exclude the
possibility of gastroesophageal disease in our patients.
In 2007, the ATS and IDSA issued revised diagnostic
criteria for NTM lung disease.2 The guidelines highlighted
the difficulty inherent in differentiating patients with
clinical lung disease caused by NTM from those in whom
the isolation of clinical specimens merely raised a clinical
suspicion of disease. In fact, NTM are ubiquitous organisms
and are frequently isolated from various environmental
sources. Currently, more than 100 NTM species have been
cataloged.2 Moreover, a great deal of variability occurs in
host susceptibility and responses to NTM infection. Thus, it
would be unreasonable to expect that a single set of
diagnostic criteria would be useful or accurate for all NTM
species with a wide spectrum of virulence in humans.2
The present study found that M. fortuitum usually caused
colonization or transient infection, rather than progressive
pulmonary disease, in patients with underlying lung diseasesuch as bronchiectasis. In 182 patients with positive cultures
for M. fortuitum from respiratory specimens, only 26
patients (14%) had two or more positive culture findings.
NTM can be inhaled as aerosol droplets and so may be
cultured if a sputum sample is obtained soon after an
environmental exposure, which probably accounts for most
of the single isolates found. Moreover, although most of
these 26 patients with more than two positive culture
findings did not receive specific prolonged antibiotic therapy
for M. fortuitum pulmonary infection, they did not show
progression of the infection. Indeed, 11 patients had three
or more positive culture findings for M. fortuitum and eight
patients showed positive AFB smear status. Our findings
suggest a low pathogenicity of this organism. Thus, even
after obtaining multiple M. fortuitum respiratory isolates,
doubt may persist about the significance of these isolates in
the absence of a clear, pre-disposing condition, such as
achalasia or recurrent aspiration.
M. fortuitum isolates are usually susceptible to multiple
oral anti-microbial agents, including the newer macrolides
(clarithromycin, azithromycin), fluoroquinolones, doxycy-
cline, and sulfonamides. For M. fortuitum lung disease,
therapy with at least two anti-microbial agents with in vitro
activity against the clinical isolate are recommended to be
given for at least 12 months of negative sputum cultures.2
However, the present study suggests that prolonged anti-
biotic therapy may not be necessary for most patients with
M. fortuitum isolates from respiratory samples. For these
patients, M. fortuitum infection can be viewed as coloniza-
tion or a transient infection and less aggressive treatment
strategies may be appropriate.
In conclusion, M. fortuitum usually causes colonization or
transient infection in patients with underlying lung disease,
such as bronchiectasis or prior tuberculosis. The majority of
these patients may not need to receive prolonged antibiotic
therapy for M. fortuitum isolates.
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